par Loi, Sherene ;Dafni, Urania;Karlis, Dimitris;Polydoropoulou, Varvara;Young, Brandon M;Willis, Scooter;Long, Bradley;de Azambuja, Evandro ;Sotiriou, Christos ;Viale, Giuseppe;Rüschoff, Josef;Piccart-Gebhart, Martine ;Dowsett, Mitch;Michiels, Stefan ;Leyland-Jones, Brian
Référence JAMA oncology
Publication Publié, 2016-04
Référence JAMA oncology
Publication Publié, 2016-04
Article révisé par les pairs
Résumé : | A number of studies suggest that response to antihuman epidermal growth factor receptor-2 (currently known as ERBB2, butreferred to asHER2 in this study) agents differs by estrogen receptor (ER) level status. The clinical relevance of this is unknown. |